Business Wire

Menicon’s Largest Malaysia Plant Begins Commercial Production

5.2.2026 10:00:00 CET | Business Wire | Press release

Share

- Strengthening Global Production Capacity for the Rapidly Growing 1-Day Lens Market

Menicon Co., Ltd. is pleased to announce that its new manufacturing facility in Kedah, Malaysia, has commenced commercial production. The plant strengthens Menicon’s long-standing commitment to technological excellence, uncompromising quality, and a stable global supply of contact lenses.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127294120/en/

The newly opened Malaysia plant is Menicon’s largest site to date and is dedicated exclusively to producing 1-DAY lenses.
As global demand for 1-DAY lenses continues rising and the industry faces widespread supply constraints, Menicon has made significant capital investments to expand production capacity—even amid the uncertainties presented by the COVID-19 pandemic.
Construction of phase 1, currently underway, will provide capacity for up to 500 million lenses per year. The construction plan is strategically formulated to extend through phase 4, allowing for further expansion in response to future market demand. With the continued installation of additional production lines, the company envisions a system capable of producing up to 2 billion lenses annually in the future.

Meanwhile, Menicon is strengthening its production capabilities for 1-DAY lenses at its facilities in Singapore and at the Kakamigahara plant in Japan.
While the company produced approximately 400 million 1-DAY lenses in FY2024, it plans to increase its production capacity by approximately 1.5 times through multi-site expansion. Subsequently, the company intends to further expand production to meet global demand.
Please refer to the attached document for more details on manufacturing site.

On the commencement of commercial production at the Malaysia Plant, President and CEO Koji Kawaiura commented:
“The launch of the Malaysia Plant marks a significant step forward in dramatically increasing our supply of 1-DAY lenses, a category experiencing rapidly growing demand worldwide. This new facility will enable us to accelerate strategic global partnerships that support our long-term growth.”

With the start of commercial production, Menicon will further strengthen its ability to deliver high‑quality products—rooted in Japanese craftsmanship and precision manufacturing, the company’s signature SMART TOUCH™ technology—to customers across Europe, North America, other global markets, and Japan.
As the global market for 1-DAY lenses continues to grow, Menicon aims to further enhance its presence and continue creating long‑term value for society by providing better vision to people around the world.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260127294120/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Introduces Maestro Agent Studio, Unlocking Next Level Decision Making Through Composable AI Agents5.2.2026 13:01:00 CET | Press release

These composable AI agents reflect how supply chains actually operate Kinaxis® Inc. (TSX: KXS), the leader in supply chain orchestration, today announced Maestro Agent Studio, making the next phase of its AI agent strategy available to customers following the launch of prebuilt Maestro Agents. Maestro Agent Studio gives supply chain teams a no-code way to compose AI agents grounded in their real operating context, using the same data, workflows, and tools planners already rely on, so agents drive real-world outcomes. Built into the Kinaxis Maestro® platform, Maestro Agent Studio enables supply chain teams and leaders to apply their expertise across every day and high-impact supply chain decisions without relying on manual, repetitive tasks or custom code development. Maestro Agent Studio is designed to work with leading large language models, including OpenAI’s GPT and Google Gemini, while keeping agent behavior anchored in Maestro’s trusted data, intelligence, and governance. The real

Introducing RAVE Aerospace: A New Name, Built on a Legacy of In-Flight Innovation5.2.2026 13:00:00 CET | Press release

Kingswood Capital Management completes acquisition of Safran Passenger Innovations and unveils the new RAVE Aerospace name, reflecting the company’s strong heritage of innovation and positioning it for the next phase of growth For nearly two decades, RAVE has been a trusted name in in-flight entertainment and connectivity for customers around the world. Today, that heritage continues under a new company name: RAVE Aerospace. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205748681/en/ Kingswood Capital Management, LP (together with its affiliates, “Kingswood”) has completed its acquisition of Safran Passenger Innovations (“SPI”), a leading global provider of in-flight entertainment and connectivity solutions, from Safran, an international aerospace group. As part of the transaction, SPI has been renamed as RAVE Aerospace, which will continue to build on the established RAVE brand that has powered in-flight entertainment a

Ryan Expands UK Business Rates and Property Tax Capabilities with Acquisition of WYM Rating5.2.2026 09:00:00 CET | Press release

Ryan, a leading global tax services and software provider, is pleased to announce the acquisition of Williams Young McKaig Ltd, a specialized commercial property consultancy, and its specialist rating division, WYM Rating, based in Edinburgh. The acquisition establishes Ryan’s property tax and business rates presence in Scotland and expands the Firm’s ability to serve clients with complex commercial property portfolios across the United Kingdom. Founded in 2012 by Richard Williams, Don Young, and Billy McKaig, WYM Rating is recognized for its client-centered approach and deep expertise across commercial property advisory. The consultancy supports landlords, occupiers, and investors through practical, market-informed advice grounded in decades of hands-on experience. WYM Rating’s capabilities span three focus areas, closely aligning with Ryan’s capabilities: Business rates and property tax Commercial property advisory Occupier and lease advisory “WYM Rating brings exactly the kind of sp

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye